Clover Health Investments Set for 'Strong' 2025 Revenue Guidance, UBS Says

MT Newswires Live2025-02-25

Clover Health Investments (CLOV) is poised for "strong" 2025 revenue guidance with the outlook for the medical loss ratio "less clear," UBS Securities said Monday in a report.

In Q4 results set for Thursday, "the focus will be on how the company's newfound growth will translate for MLR" and adjusted earnings before interest, taxes, depreciation and amortization, UBS said.

Growth for 2025 "was noted to have come largely from switchers, which should provide for improved economics" relative to new to Medicare Advantage members," UBS said.

The "relatively positive" Advance Medicare Advantage notice for 2026 may boost revenue in 2026, leaving the company on an "upward trajectory," the report said.

UBS raised its price target on Clover Health to $4.50 from $4 and maintained its neutral rating.

Price: 4.23, Change: -0.18, Percent Change: -3.98

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2514556703?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-25 04:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2514556703","market":"fut","top_or_hot":-1,"title":"Clover Health Investments Set for 'Strong' 2025 Revenue Guidance, UBS Says","media":"MT Newswires Live","content":"<html><body><p> Clover Health Investments (CLOV) is poised for \"strong\" 2025 revenue guidance with the outlook for the medical loss ratio \"less clear,\" UBS Securities said Monday in a report.</p><p>In Q4 results set for Thursday, \"the focus will be on how the company's newfound growth will translate for MLR\" and adjusted earnings before interest, taxes, depreciation and amortization, UBS said.</p><p>Growth for 2025 \"was noted to have come largely from switchers, which should provide for improved economics\" relative to new to Medicare Advantage members,\" UBS said.</p><p>The \"relatively positive\" Advance Medicare Advantage notice for 2026 may boost revenue in 2026, leaving the company on an \"upward trajectory,\" the report said.</p><p>UBS raised its price target on Clover Health to $4.50 from $4 and maintained its neutral rating.</p><p>Price: 4.23, Change: -0.18, Percent Change: -3.98</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clover Health Investments Set for 'Strong' 2025 Revenue Guidance, UBS Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClover Health Investments Set for 'Strong' 2025 Revenue Guidance, UBS Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-02-25 04:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Clover Health Investments (CLOV) is poised for \"strong\" 2025 revenue guidance with the outlook for the medical loss ratio \"less clear,\" UBS Securities said Monday in a report.</p><p>In Q4 results set for Thursday, \"the focus will be on how the company's newfound growth will translate for MLR\" and adjusted earnings before interest, taxes, depreciation and amortization, UBS said.</p><p>Growth for 2025 \"was noted to have come largely from switchers, which should provide for improved economics\" relative to new to Medicare Advantage members,\" UBS said.</p><p>The \"relatively positive\" Advance Medicare Advantage notice for 2026 may boost revenue in 2026, leaving the company on an \"upward trajectory,\" the report said.</p><p>UBS raised its price target on Clover Health to $4.50 from $4 and maintained its neutral rating.</p><p>Price: 4.23, Change: -0.18, Percent Change: -3.98</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CLOV","symbol_name":"Clover Health Corp","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2514556703","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2514556703","pubTimestamp":1740428714,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Clover Health Investments  is poised for \"strong\" 2025 revenue guidance with the outlook for the medical loss ratio \"less clear,\" UBS Securities said Monday in a report.In Q4 results set for Thursday, \"the focus will be on how the company's newfound growth will translate for MLR\" and adjusted earnings before interest, taxes, depreciation and amortization, UBS said.Growth for 2025 \"was noted to have come largely from switchers, which should provide for improved economics\" relative to new to Medicare Advantage members,\" UBS said.The \"relatively positive\" Advance Medicare Advantage notice for 2026 may boost revenue in 2026, leaving the company on an \"upward trajectory,\" the report said.UBS raised its price target on Clover Health to $4.50 from $4 and maintained its neutral rating.Price: 4.23, Change: -0.18, Percent Change: -3.98","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"CLOV":"Clover Health Corp"},"translate_title":"瑞银表示，Clover Health Investments 2025年收入指引将达到“强劲”","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CLOV":0.9},"content_text":"Clover Health Investments (CLOV) is poised for \"strong\" 2025 revenue guidance with the outlook for the medical loss ratio \"less clear,\" UBS Securities said Monday in a report.In Q4 results set for Thursday, \"the focus will be on how the company's newfound growth will translate for MLR\" and adjusted earnings before interest, taxes, depreciation and amortization, UBS said.Growth for 2025 \"was noted to have come largely from switchers, which should provide for improved economics\" relative to new to Medicare Advantage members,\" UBS said.The \"relatively positive\" Advance Medicare Advantage notice for 2026 may boost revenue in 2026, leaving the company on an \"upward trajectory,\" the report said.UBS raised its price target on Clover Health to $4.50 from $4 and maintained its neutral rating.Price: 4.23, Change: -0.18, Percent Change: -3.98","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2514556703","isCrawlerRequest":true}